Ascendis Pharma is applying its innovative technology platform to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patientsâ lives. The company utilizes its TransCon technology with clinically validated parent drugs to create new therapies with potential for best-in-class efficacy, safety and/or convenience. Ascendis Pharma has a pipeline of three independent, rare disease endocrinology product candidates in clinical development, and has established oncology as its second therapeutic area of focus. Source
No articles found.
Esperion is a pharmaceutical company passionately committed to developing and comm...
Esperion is a pharmaceutical company passionate...
Benitec is a biotechnology company developing a proprietary therapeutic technology...
Benitec is a biotechnology company developing a...
The discovery of immunosuppressive (anti-rejection) drugs has made possible life-s...
The discovery of immunosuppressive (anti-reject...
Neos Therapeutics develops, manufactures, and commercializes innovative extended-r...
Neos Therapeutics develops, manufactures, and c...
Conatus Pharmaceuticals is a biotechnology company focused on the development and ...
Conatus Pharmaceuticals is a biotechnology comp...
Genocea is a biopharmaceutical company developing personalized cancer immunotherap...
Genocea is a biopharmaceutical company developi...
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the d...
Viking Therapeutics is a clinical-stage biophar...
Aeterna Zentaris is a specialty biopharmaceutical company focused on developing an...
Aeterna Zentaris is a specialty biopharmaceutic...
Crinetics is a clinical stage pharmaceutical company focused on the discovery, dev...
Crinetics is a clinical stage pharmaceutical co...
Progenics develops innovative medicines and other technologies to target and treat...
Progenics develops innovative medicines and oth...
Join the National Investor Network and get the latest information with your interests in mind.